Literature DB >> 23327477

Role of lysine during protein modification by HOCl and HOBr: halogen-transfer agent or sacrificial antioxidant?

John D Sivey1, Stanley C Howell, Doyle J Bean, Daniel L McCurry, William A Mitch, Corey J Wilson.   

Abstract

Although protein degradation by neutrophil-derived hypochlorous acid (HOCl) and eosinophil-derived hypobromous acid (HOBr) can contribute to the inactivation of pathogens, collateral damage to host proteins can also occur and has been associated with inflammatory diseases ranging from arthritis to atherosclerosis. Though previous research suggested halotyrosines as biomarkers of protein damage and lysine as a mediator of the transfer of a halogen to tyrosine, these reactions within whole proteins are poorly understood. Herein, reactions of HOCl and HOBr with three well-characterized proteins [adenylate kinase (ADK), ribose binding protein, and bovine serum albumin] were characterized. Three assessments of oxidative modifications were evaluated for each of the proteins: (1) covalent modification of electron-rich amino acids (assessed via liquid chromatography and tandem mass spectrometry), (2) attenuation of secondary structure (via circular dichroism), and (3) fragmentation of protein backbones (via sodium dodecyl sulfate-polyacrylamide gel electrophoresis). In addition to forming halotyrosines, HOCl and HOBr converted lysine into lysine nitrile (2-amino-5-cyanopentanoic acid), a relatively stable and largely overlooked product, in yields of up to 80%. At uniform oxidant levels, fragmentation and loss of secondary structure correlated with protein size. To further examine the role of lysine, a lysine-free ADK variant was rationally designed. The absence of lysine increased yields of chlorinated tyrosines and decreased yields of brominated tyrosines following treatments with HOCl and HOBr, respectively, without influencing the susceptibility of ADK to HOX-mediated losses of secondary structure. These findings suggest that lysine serves predominantly as a sacrificial antioxidant (via formation of lysine nitrile) toward HOCl and as a halogen-transfer mediator [via reactions involving ε-N-(di)haloamines] with HOBr.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23327477     DOI: 10.1021/bi301523s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Myeloperoxidase-mediated protein lysine oxidation generates 2-aminoadipic acid and lysine nitrile in vivo.

Authors:  Hongqiao Lin; Bruce S Levison; Jennifer A Buffa; Ying Huang; Xiaoming Fu; Zeneng Wang; Valentin Gogonea; Joseph A DiDonato; Stanley L Hazen
Journal:  Free Radic Biol Med       Date:  2017-01-06       Impact factor: 7.376

Review 2.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

3.  Leveraging the Mechanism of Oxidative Decay for Adenylate Kinase to Design Structural and Functional Resistances.

Authors:  Stanley C Howell; David H Richards; William A Mitch; Corey J Wilson
Journal:  ACS Chem Biol       Date:  2015-08-17       Impact factor: 5.100

4.  Computational design of bio-inspired carnosine-based HOBr antioxidants.

Authors:  Farzaneh Sarrami; Li-Juan Yu; Amir Karton
Journal:  J Comput Aided Mol Des       Date:  2017-09-08       Impact factor: 3.686

5.  Role of cysteines in the stability and DNA-binding activity of the hypochlorite-specific transcription factor HypT.

Authors:  Adrian Drazic; Amelie Tsoutsoulopoulos; Jirka Peschek; Jasmin Gundlach; Maike Krause; Nina C Bach; Katharina M Gebendorfer; Jeannette Winter
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

6.  N-chlorination mediates protective and immunomodulatory effects of oxidized human plasma proteins.

Authors:  Agnes Ulfig; Anton V Schulz; Alexandra Müller; Natalie Lupilov; Lars I Leichert
Journal:  Elife       Date:  2019-07-12       Impact factor: 8.140

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.